NovoCure Ltd (FRA:038)
€ 16.225 -0.425 (-2.55%) Market Cap: 1.75 Bil Enterprise Value: 1.48 Bil PE Ratio: 0 PB Ratio: 5.23 GF Score: 69/100

Novocure Ltd at Wells Fargo Virtual Healthcare Conference Transcript

Sep 10, 2021 / 02:40PM GMT
Release Date Price: €111.95 (-1.50%)
Operator

Welcome to the Wells Fargo Healthcare Conference. Before we get started, if you are a member of the press or media, please disconnect at this time. This is a restricted line. Any unauthorized party in this meeting or any unauthorized use of the information communicated in this meeting is subject to prosecution to the fullest extent of the law. Any unauthorized person, including the media that is on the line at this time, please disconnect. Please note, today's call is being recorded.

Lawrence H. Biegelsen
Wells Fargo Securities, LLC, Research Division - Senior Medical Device Equity Research Analyst

Good morning. I'm Larry Biegelsen, the medical device analyst at Wells Fargo, and it's my pleasure to host this session with the management team from NovoCure. With us, we have Ashley Cordova, the CFO; and Tesh Shah, who is the Chief Commercial Officer.

In terms of format, it's going to be a fireside chat. If anybody who has a question they want me to ask on their behalf, please email it to me, and I think we're going to try to do some polling questions

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot